Acylcarnitine and insulin resistance: does y-butyrobetaine enhance fatty acid oxidation and influence acylcarnitine profiles?

Acylcarnitine and insulin resistance: does y-butyrobetaine enhance fatty acid oxidation and influence acylcarnitine profiles? - AIR-study: y-BB

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON36950

Enrollment

Registered

2013-04-03

Start date

2013-04-11

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesitas insulin insensitivity Insulin resistance

Interventions

Administration of an oral dose of the nutritional supplement y-butyrobetaine, for 14 days on a daily basis.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1- Healthy lean and obese (BMI 19-25 kg/m2 and >30 kg/m2 respectively) volunteers 2- Adult age (>18 years of age) 3- Normal liver and renal function 4- Informed consent

Exclusion criteria

Exclusion criteria: 1- Treated diabetes 2- HbA1c >8% 3- Any medication interfering with insulin sensitivity (steroids, beta-blockers) 4- Intensive sports (> three times weekly intensive training) 5- Any medical disorder of significant relevance 6- DM II in first degree family members 7- Hypertriglyceridemia or any other lipid metabolism disorder

Design outcomes

Primary

Measure	Time frame
- Free carnitine levels (before/after y-BB administration) - Acylcarnitine profiles (before/after y-BB administration)	—

Secondary

Measure	Time frame
- Fatty Acid oxidation rate (before/after y-BB administration) - Insulin sensitivity (before/after y-BB administration)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)